DK1311677T3 - Regulering af human P2Y-1-lignende G-proteinkoblet receptor - Google Patents

Regulering af human P2Y-1-lignende G-proteinkoblet receptor

Info

Publication number
DK1311677T3
DK1311677T3 DK01976066T DK01976066T DK1311677T3 DK 1311677 T3 DK1311677 T3 DK 1311677T3 DK 01976066 T DK01976066 T DK 01976066T DK 01976066 T DK01976066 T DK 01976066T DK 1311677 T3 DK1311677 T3 DK 1311677T3
Authority
DK
Denmark
Prior art keywords
protein
asthma
disease
coupled receptor
human
Prior art date
Application number
DK01976066T
Other languages
English (en)
Inventor
Shyam Ramakrishnan
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1311677T3 publication Critical patent/DK1311677T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
DK01976066T 2000-08-14 2001-08-10 Regulering af human P2Y-1-lignende G-proteinkoblet receptor DK1311677T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22498900P 2000-08-14 2000-08-14

Publications (1)

Publication Number Publication Date
DK1311677T3 true DK1311677T3 (da) 2006-05-22

Family

ID=22843078

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01976066T DK1311677T3 (da) 2000-08-14 2001-08-10 Regulering af human P2Y-1-lignende G-proteinkoblet receptor

Country Status (9)

Country Link
US (3) US20040038879A1 (da)
EP (1) EP1311677B8 (da)
JP (1) JP2004506426A (da)
AT (1) ATE315089T1 (da)
AU (1) AU2001295454A1 (da)
DE (1) DE60116515T2 (da)
DK (1) DK1311677T3 (da)
ES (1) ES2258553T3 (da)
WO (1) WO2002014511A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258553T3 (es) * 2000-08-14 2006-09-01 Actimis Pharmaceuticals, Inc. Regulacion del receptor acoplado a la proteina g humana del tipo p2y1.
US7312086B2 (en) 2000-12-07 2007-12-25 Bristol-Myers Squibb Company Methods of diagnosing colon adenocarcinoma using the human g-protein coupled receptor hgprbmy23
US20060240424A1 (en) * 2002-09-27 2006-10-26 Hisayo Inbe Regulation of human p2y15 g protein-coupled receptor
US7056685B1 (en) 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
WO2005101004A2 (en) * 2004-04-13 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with purinoceptor 1 type y (p2y1)
WO2006052007A1 (ja) * 2004-11-11 2006-05-18 Takeda Pharmaceutical Company Limited 血糖調節剤
CN107596371B (zh) * 2017-08-21 2021-01-26 南方医科大学 P2y1受体及其阻断剂在预防和治疗抗抑郁症和/或抗焦虑症中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981176A (en) * 1992-06-17 1999-11-09 City Of Hope Method of detecting and discriminating between nucleic acid sequences
FR2701955B1 (fr) * 1993-02-26 1995-05-24 Paris Val Marne Universite Facteur de croissance de la famille de l'HARP, procédé d'obtention et applications.
US5582988A (en) * 1994-09-15 1996-12-10 Johnson & Johnson Clinical Diagnostics, Inc. Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same
US5734040A (en) * 1996-03-21 1998-03-31 University Of Iowa Research Foundation Positively charged oligonucleotides as regulators of gene expression
US6924040B2 (en) * 1996-12-12 2005-08-02 United Technologies Corporation Thermal barrier coating systems and materials
CA2388865A1 (en) * 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Novel g protein-coupled receptors
IL149569A0 (en) * 1999-11-17 2002-11-10 Arena Pharm Inc Endogenous and non-endogenous versions of human g protein-coupled receptors
EP1246916A2 (en) * 1999-12-30 2002-10-09 Millennium Pharmaceuticals, Inc. 26904, 38911, and 39404, seven-transmembrane proteins / g-protein coupled receptors
AU2001234944A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001243142A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1261710A2 (en) * 2000-03-08 2002-12-04 PHARMACIA & UPJOHN COMPANY G protein-coupled receptors
EP1297128A2 (en) * 2000-05-18 2003-04-02 Incyte Genomics, Inc. G-protein coupled receptors
WO2001087980A2 (en) * 2000-05-18 2001-11-22 Applera Corporation Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
ES2258553T3 (es) * 2000-08-14 2006-09-01 Actimis Pharmaceuticals, Inc. Regulacion del receptor acoplado a la proteina g humana del tipo p2y1.

Also Published As

Publication number Publication date
ES2258553T3 (es) 2006-09-01
EP1311677B8 (en) 2006-04-19
ATE315089T1 (de) 2006-02-15
US20050148014A1 (en) 2005-07-07
WO2002014511A3 (en) 2002-07-11
US20040038879A1 (en) 2004-02-26
EP1311677A2 (en) 2003-05-21
US20060052329A1 (en) 2006-03-09
DE60116515D1 (de) 2006-03-30
EP1311677B1 (en) 2006-01-04
DE60116515T2 (de) 2006-09-07
WO2002014511A2 (en) 2002-02-21
JP2004506426A (ja) 2004-03-04
AU2001295454A1 (en) 2002-02-25

Similar Documents

Publication Publication Date Title
EP0867508A3 (en) Olfactory receptor of the 7-transmembrane receptor family - OLRCC15 receptor
EP0893498A3 (en) cDNA clone MY1 that encodes a novel human 7-transmembrane receptor
EP1154019A3 (en) G-protein coupled receptor (HFGAN72X)
EP0875565A3 (en) Novel G-protein coupled receptor (hfgan72y)
EP0892051A3 (en) CDNA Clone heoad54 that encodes a human 7 transmembrane receptor
EP0899332A3 (en) The G-protein coupled receptor HFIAO41
EP0848060A3 (en) Novel human 11CB splice variant
WO2001094385A8 (en) Human hm74-like g protein coupled receptor
WO2001077320A3 (en) Regulation of human hm74-like g protein coupled receptor
DE60116515D1 (de) Regulierung des menschlichen p2y1-ähnlichen g-protein gekoppelten rezeptors
EP0885960A3 (en) G-protein coupled receptor (H7TBA62)
EP0913471A3 (en) Cdna clone HNEAA81 that encodes a human 7-transmembrane receptor
WO2001070814A3 (en) Regulation of human rta-like g protein-coupled receptor
EP0881289A3 (en) Novel 7TM receptor (H2CAA71)
DK1287137T3 (da) Regulation af human alfa1A-adrenergreceptorlignende G-proteinkoblet receptor
WO2001070971A3 (en) Regulation of human mas oncogene-related g protein-coupled receptor
WO2001068702A3 (en) Regulation of human g protein-coupled receptor
WO2001004139A3 (en) Human axor29 receptor
WO2001068842A3 (en) Regulation of human p2y-like gpcr protein
WO2001085764A3 (en) Regulation of human p2y-like g protein-coupled receptor
WO2001068701A3 (en) Regulation of human seven transmembrane - like g protein - coupled receptor (7tm-gpcr)
EP0894854A3 (en) A novel splicing variant of the epstein-barr virus-induced g-protein coupled receptor
WO2002000700A3 (en) Regulation of human p2y8-like g protein-coupled receptor
EP0878542A3 (en) cDNA clone HMTMF81 that encodes a novel human 7-transmembrane receptor
EP0853125A3 (en) cDNA clone HNFJD15 that encodes a human 7-transmembrane receptor